Fukagawa M - Search Results

1

Efficacy and Safety of Upacicalcet in Hemodialysis Patients with Secondary Hyperparathyroidism: A Randomized Placebo-Controlled Trial.

Shigematsu T, Koiwa F, Isaka Y, Fukagawa M, Hagita K, Watanabe YS, Honda D, Akizawa T. Shigematsu T, et al. Among authors: fukagawa m. Clin J Am Soc Nephrol. 2023 Oct 1;18(10):1300-1309. doi: 10.2215/CJN.0000000000000253. Epub 2023 Sep 11. Clin J Am Soc Nephrol. 2023. PMID: 37696667 Free PMC article. Clinical Trial.

2

Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure.

Kazama JJ, Shigematsu T, Yano K, Tsuda E, Miura M, Iwasaki Y, Kawaguchi Y, Gejyo F, Kurokawa K, Fukagawa M. Kazama JJ, et al. Among authors: fukagawa m. Am J Kidney Dis. 2002 Mar;39(3):525-32. doi: 10.1053/ajkd.2002.31402. Am J Kidney Dis. 2002. PMID: 11877571

3

The negative Ca(2+) balance is involved in the stimulation of PTH secretion.

Yokoyama K, Kagami S, Ohkido I, Kato N, Yamamoto H, Shigematsu T, Nakayama M, Fukagawa M, Kawaguchi Y, Hosoya T. Yokoyama K, et al. Among authors: fukagawa m. Nephron. 2002 Sep;92(1):86-90. doi: 10.1159/000064484. Nephron. 2002. PMID: 12187089

4

Management of patients with advanced secondary hyperparathyroidism: the Japanese approach.

Fukagawa M, Kazama JJ, Shigematsu T. Fukagawa M, et al. Nephrol Dial Transplant. 2002 Sep;17(9):1553-7. doi: 10.1093/ndt/17.9.1553. Nephrol Dial Transplant. 2002. PMID: 12198204 Review. No abstract available.

5

IRMA (whole PTH) is a more useful assay for the effect of PTH on bone than the Allegro intact PTH assay in CAPD patients with low bone turnover marker.

Tanno Y, Yokoyama K, Nakayama M, Katoh A, Yamamoto H, Iwasaki Y, Cantor T, Fukagawa M, Shigematsu T, Hosoya T. Tanno Y, et al. Among authors: fukagawa m. Nephrol Dial Transplant. 2003 Jun;18 Suppl 3:iii97-8. doi: 10.1093/ndt/gfg1025. Nephrol Dial Transplant. 2003. PMID: 12771313

6

Circulating 1-84 PTH and large C-terminal PTH fragment levels in uremia.

Kazama JJ, Omori T, Ei I, Ei K, Oda M, Maruyama H, Narita I, Gejyo F, Shigematsu T, Fukagawa M. Kazama JJ, et al. Among authors: fukagawa m. Clin Exp Nephrol. 2003 Jun;7(2):144-9. doi: 10.1007/s10157-003-0226-2. Clin Exp Nephrol. 2003. PMID: 14586733

7

Extracorporeal albumin dialysis.

Abe T, Shono M, Kodama T, Kita Y, Fukagawa M, Akizawa T. Abe T, et al. Among authors: fukagawa m. Ther Apher Dial. 2004 Jun;8(3):217-22. doi: 10.1111/j.1526-0968.2004.00148.x. Ther Apher Dial. 2004. PMID: 15154874

8

Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency.

Shigematsu T, Kazama JJ, Yamashita T, Fukumoto S, Hosoya T, Gejyo F, Fukagawa M. Shigematsu T, et al. Among authors: fukagawa m. Am J Kidney Dis. 2004 Aug;44(2):250-6. doi: 10.1053/j.ajkd.2004.04.029. Am J Kidney Dis. 2004. PMID: 15264182

9

Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients.

Nakanishi S, Kazama JJ, Nii-Kono T, Omori K, Yamashita T, Fukumoto S, Gejyo F, Shigematsu T, Fukagawa M. Nakanishi S, et al. Among authors: fukagawa m. Kidney Int. 2005 Mar;67(3):1171-8. doi: 10.1111/j.1523-1755.2005.00184.x. Kidney Int. 2005. PMID: 15698459 Free article.

10

How to apply and adapt international guidelines on bone metabolism and disease to the management of Japanese dialysis patients.

Fukagawa M, Akizawa T. Fukagawa M, et al. Ther Apher Dial. 2005 Feb;9(1):1-2. doi: 10.1111/j.1774-9987.2005.00204.x. Ther Apher Dial. 2005. PMID: 15828896 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

620 results

Search Page

Filters